Regenxbio (RGNX) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US75901B1070

Gene, Therapies, Delivery, Platform, Virus

REGENXBIO Inc. is a pioneering biotechnology company that develops innovative gene therapies to treat genetic defects. Using its proprietary NAV Technology Platform, a cutting-edge adeno-associated virus gene delivery platform, the company creates life-changing treatments for various debilitating diseases.

The company's pipeline is filled with promising products, including ABBV-RGX-314, which is being developed to combat wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases. Another product, RGX-202, is in Phase I/II clinical trials to treat Duchenne muscular dystrophy, a devastating genetic disorder that affects children.

REGENXBIO is also working on RGX-121, a treatment for mucopolysaccharidosis type II, which is currently in Phase III clinical trials. Additionally, the company is developing RGX-111 to treat mucopolysaccharidosis type I, RGX-181 to treat late infantile neuronal ceroid lipofuscinosis type II, and RGX-381 to address the ocular manifestations of CLN2 disease.

What's more, REGENXBIO licenses its groundbreaking NAV Technology Platform to other biotechnology and pharmaceutical companies, enabling them to develop their own gene therapies. The company has also partnered with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States, expanding its global reach.

Founded in 2008, REGENXBIO is headquartered in Rockville, Maryland, and is committed to revolutionizing the field of gene therapy. To learn more about the company's mission and innovative products, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Regenxbio (RGNX) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Regenxbio (RGNX) - Stock Price & Dividends

RGNX Stock Overview

Market Cap in USD 672m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2015-09-17

RGNX Stock Ratings

Growth 5y -65.3
Fundamental -69.0
Dividend -
Rel. Performance vs Sector -5.35
Analysts 4.42/5
Fair Price Momentum 9.13 USD
Fair Price DCF -

RGNX Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

RGNX Growth Ratios

Growth 12m -36.40%
Growth Correlation 12m -23%
Growth Correlation 3m -83%
CAGR 5y -24.79%
CAGR/Mean DD 5y -0.56
Sharpe Ratio 12m -0.67
Alpha vs SP500 12m -73.74
Beta vs SP500 5y weekly 1.44
ValueRay RSI 17.75
Volatility GJR Garch 1y 63.31%
Price / SMA 50 -21.23%
Price / SMA 200 -29.91%
Current Volume 2109.9k
Average Volume 20d 640k

External Links for RGNX Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of RGNX stocks?
As of June 22, 2024, the stock is trading at USD 12.02 with a total of 2,109,856 shares traded.
Over the past week, the price has changed by -3.14%, over one month by -21.59%, over three months by -46.58% and over the past year by -37.82%.
What are the forecast for RGNX stock price target?
According to ValueRays Forecast Model, RGNX Regenxbio will be worth about 10.2 in June 2025. The stock is currently trading at 12.02. This means that the stock has a potential downside of -15.47%.
Issuer Forecast Upside
Wallstreet Target Price 38.8 222
Analysts Target Price 41.6 246
ValueRay Target Price 10.2 -15.5